Xyz interventions: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Andersen-Tawil syndrome}} | ||
{{CMG}}; | {{CMG}}; {{AE}} {{VKG}} | ||
==Overview== | ==Overview== | ||
| Line 8: | Line 8: | ||
OR | OR | ||
Cardioverter-defibrillator is not the first-line treatment option for patients with Andersen-Tawil syndrome (ATS) . Cardioverter-defibrillator is usually reserved for patients with tachycardia-induced syncope. | |||
OR | OR | ||
Revision as of 14:27, 12 February 2020
|
Andersen-Tawil syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Xyz interventions On the Web |
|
American Roentgen Ray Society Images of Xyz interventions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
There are no recommended therapeutic interventions for the management of [disease name].
OR
Cardioverter-defibrillator is not the first-line treatment option for patients with Andersen-Tawil syndrome (ATS) . Cardioverter-defibrillator is usually reserved for patients with tachycardia-induced syncope.
OR
The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
OR
The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.
OR
[Name of intervention] is the mainstay of treatment for [disease or malignancy].
Indications
The mainstay of treatment for TT is medical therapy.